Document is current
Any future updates will be listed below
-
Authors
Bernadette, Brennan https://orcid.org/0009-0003-2805-8079
Kirton, Laura
Marec-Bérard, Perrine
Gaspar, Nathalie https://orcid.org/0000-0002-1827-8903
Laurence, Valerie
Martín-Broto, Javier
Gelderblom, Hans
Owens, Cormac
Anderton, Jennifer
Strauss, Sandra J.
Wingrove, Jane
Moroz, Veronica
Whelan, Jeremy
Hjalgrim, Lisa L.
Wheatley, Keith
Gaunt, Piers https://orcid.org/0000-0001-8665-300X
-
Funding
Funding for this research was provided by:
Cancer Research UK
European Union's seventh framework programme Technological Articles Development, and Demonstration French society paediatric oncology Ligue contre le cancer
- License Information
-
More Information
Article History
Received: 7 May 2025
Revised: 15 January 2026
Accepted: 19 February 2026
First Online: 15 March 2026
Competing interests
: LK declares grant funding from Cancer Research UK and Bayer unrelated to this work. JM-B reports institutional grants from PharmaMar, Lilly, Lixte Biotecnologia, Terapeutica Karyopharm, Deciphera, Bristol Myers-Squibb, Pfizer, Inhibrx, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, RAN Therapeutics, Boehringer Ingelheim, Synox, Abbisko, Biosplice, Immunome, BMS, SpringWorks Therapeutics; royalties/licences from PharmaMar; consulting fees from PharmaMar, Glaxosmithkline, Bayer, Roche, Tecnofarma, Asofarma, Boehringer Ingelheim, Cogent Biosciences, Deciphera; honoraria from Pharmamar; payment for expert testimony from PharmaMar, Glaxosmithkline, Bayer, Roche, Tecnofarma, Asofarma, Boehringer Ingelheim, Cogent Biosciences, Deciphera; support for meetings from PharmaMar; and leadership role for Sarcoma Research Solutions SL. SJS declares honoraria from Boehringer Ingelheim and participation on a safety monitoring board for Ipsen; Inhibrx; Tessallate Bio; Awen Oncology and Ewing Sarcoma Institute. VM has since moved employment, but her new employer has no relationship with this work. PG declares grant funding from Cancer Research UK and Bayer unrelated to this work. We declare no other competing interests.
: The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. Informed written consent was obtained from all patients/parents/legal guardians as per local practice. Before commencing the study, approval was gained from the relevant competent authority and ethical committee in each country. The trial was prospectively registered with EudraCT 2012-002107-17 and ISRCTN 54540667.
